Discovering FFC-MRI Biomarkers of Alzheimer Disease

Alzheimer Disease Clinical Trial

Official title:

Non-invasive In-vivo Characterisation of Alzheimer's Disease Using Fast-field Cycling Magnetic Resonance Imaging (FFC MRI)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05220150
• Other study ID #: 2-031-16
• Status: Terminated
• Phase: N/A
• Start date: October 17, 2017
• Est. completion date: September 1, 2021

Study information

• Verified date: February 2022
• Source: University of Aberdeen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fast Field-Cycling MRI (FFC MRI) is a new scanning technology being developed at the University of Aberdeen. Previous pilot studies by the team on osteoarthritis, breast cancer, musculoskeletal cancer, liver fibrosis, thrombosis and muscle damage have demonstrated that FFC MRI provides useful information for clinical diagnostics in a variety of pathologies.

The aim of this study is to ascertain if brain imaging with FFC MRI yields any useful information in the diagnosis and evaluation of Alzheimer's disease.

Description:

Alzheimer's disease (AD) patients and appropriate controls will be identified by consultants working with the patient group.

Potential participants will be approached by letter by their clinician. The purpose of this study will be explained to them and they will be asked for signed informed consent.

Communication between the clinical team and FFC-MRI research team will ensure that any appointment for FFC-MRI is made at a time that is convenient for the patient and clinical team.

The aim is to recruit 25 individuals with AD and 25 age matched controls.

FFC-MRI images will be acquired on dedicated equipment specifically built for the purpose of imaging human volunteers and patients. Where clinically appropriate patents will undergo other imaging procedures as part of their normal NHS care.

FFC-MRI will be compared standard clinical care data to identify regions of interest for quantitative analysis of FFC MRI data.

Anonymous personal information will be collected from the NHS patient records for stratification of the results (such as age, sex or relevant examination results)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: September 1, 2021
• Est. primary completion date: September 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 120 Years

Eligibility

Inclusion Criteria:

• Patients with probable Alzheimer's disease, based upon cognitive testing (MMSE) and SPECT imaging.

• Controls will be participants without known cognitive impairment or Alzheimer's disease.

• Subjects capable of giving informed consent.

• Age 21 and above

Exclusion Criteria:

• MRI-incompatible condition detected in the MR screening sheet such as some metallic implanted devices (see MR screening sheet in the project files).

• Claustrophobia

• Waist circumference larger than 102 cm, due to the limited bore size of the scanner.

• Restrictions to mobility such that patients are unable to be positioned in scanner by trained research radiographer e.g. severe kyphosis

• Cognitive impairment of sufficient severity that the participant does not have capacity to give informed consent

• Pregnancy

• Persons who might not adequately understand verbal explanations or written information given in English, or who have special communication needs

• Dementia of sufficient severity that the participant cannot give informed consent

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Device:
• FFC-MRI scan
Undergo one FFC-MRI scan.

Locations

Country	Name	City	State
United Kingdom	Biomedical Physics Building, Foresterhill Health Campus	Aberdeen	Scotland

Sponsors (1)

Lead Sponsor	Collaborator
University of Aberdeen

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Outcome	The FFC-MRI T1 maps of patients and controls, with SPECT findings for validation. The outcome used for the primary research question will be the statistical significance in the difference of image contrast between the control group and the patient group. The presence of AD in the patient group will be estimated using the current clinical standard, cognitive testing with MoCA) or MMSE and blood flow SPECT CT imaging. If the participant has recently had an MRI scan using 3T MRI, we will ask for permission from the participant to access these images and use them for comparison.; The level of significance of the differences will be derived using the statistical test most adapted to the contrast, depending on the distribution profile across the samples. No previous data exist to guide our choice.	12 weeks
Secondary	Secondary Outcome	Variations in the FFC-MRI biomarkers obtained for the T1 maps. The outcome of interest to fulfil our secondary objective is the estimation of the distribution of the contrast identified as potential biomarkers. This will allow us to estimate the sample size for further validation studies.	12 weeks